Kenichiro Tokunaga Noboru Hagino
10.2169/internalmedicine.56.7956
Intern Med
2017;56(11):1399-1403.
anti-ars antibody anti-mda5 antibody anti-pl-12 antibody dermatomyositis interstitial lung disease rituximab
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/28566605/
Dermatomyositis / complications Dermatomyositis / drug therapy Immunologic Factors / therapeutic use Lung Diseases, Interstitial / complications Rituximab / therapeutic use
Dermatomyositis / complications Dermatomyositis / drug therapy Immunologic Factors / therapeutic use Lung Diseases, Interstitial / complications Rituximab / therapeutic use Case Reports Aged Amino Acyl-tRNA Synthetases / immunology Autoantibodies Calcineurin Inhibitors / therapeutic use Cyclophosphamide / therapeutic use Dermatomyositis / immunology Female Glucocorticoids / therapeutic use Humans Interferon-Induced Helicase, IFIH1 / immunology Japan Lung Diseases, Interstitial / drug therapy Lung Diseases, Interstitial / immunology Retrospective Studies Autoantibodies Calcineurin Inhibitors Glucocorticoids Immunologic Factors Rituximab Cyclophosphamide IFIH1 protein, human Interferon-Induced Helicase, IFIH1 Amino Acyl-tRNA Synthetases
PMC5498206
28566605
Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan
2017